Results 51 to 60 of about 1,936 (153)

Activity of Ceftolozane–Tazobactam against Burkholderia pseudomallei [PDF]

open access: yesThe American Journal of Tropical Medicine and Hygiene, 2018
We investigated the in vitro activity of a novel fifth-generation cephalosporin–tazobactam combination, ceftolozane–tazobactam against Burkholderia pseudomallei, the etiological agent of melioidosis. Using both disc diffusion and minimum inhibitory concentration (MIC) strip techniques against 56 clinical isolates and an national collection of type ...
Slack, Andrew   +4 more
openaire   +4 more sources

An Unusual Case of Citrobacter koseri Infection During Pregnancy at 27 Weeks: A Case Report and Literature Review

open access: yesClinical Case Reports, Volume 14, Issue 4, April 2026.
ABSTRACT Early prenatal screening at 26 + 6 weeks detected Citrobacter koseri vaginal colonization in an asymptomatic high‐risk gravida. Culture‐guided IV ceftazidime (susceptible per CLSI testing) eradicated the pathogen without maternal/fetal compromise.
Mario Assenza   +2 more
wiley   +1 more source

Cost-effectiveness of ceftolozane/tazobactam plus metronidazole versus piperacillin/tazobactam as initial empiric therapy for the treatment of complicated intra-abdominal infections based on pathogen distributions drawn from national surveillance data in the United States

open access: yesAntimicrobial Resistance and Infection Control, 2017
Background The prevalence of antimicrobial resistance among gram-negative pathogens in complicated intra-abdominal infections (cIAIs) has increased. In the absence of timely information on the infecting pathogens and their susceptibilities, local or ...
Vimalanand S. Prabhu   +8 more
doaj   +1 more source

Ceftolozane/tazobactam versus meropenem in patients with ventilated hospital-acquired bacterial pneumonia: subset analysis of the ASPECT-NP randomized, controlled phase 3 trial

open access: yesCritical Care, 2021
Background Ceftolozane/tazobactam is approved for treatment of hospital-acquired/ventilator-associated bacterial pneumonia (HABP/VABP) at double the dose approved for other infection sites.
Jean-François Timsit   +14 more
doaj   +1 more source

Microbial Etiology and Antimicrobial Resistance in Pneumonia Among Hospitalized Patients in Kazakhstan: A Systematic Review and Single‐Arm Meta‐Analysis of Prevalence Data

open access: yesHealth Science Reports, Volume 9, Issue 4, April 2026.
ABSTRACT Background and Aims Pneumonia is an inflammatory condition of the lower respiratory tract, commonly caused by infection and associated with substantial morbidity and healthcare utilization. The burden of pneumonia on healthcare is exacerbated by limited data on pathogenic causes and associated antimicrobial resistance (AMR). Here, we conducted
Radmir Sarsenov   +7 more
wiley   +1 more source

Ceftolozane/tazobactam: a novel antipseudomonal cephalosporin and β-lactamase-inhibitor combination [PDF]

open access: yes, 2013
The management of infections caused by multidrug-resistant Gram-negative bacteria, particularly Pseudomonas aeruginosa, continues to be a significant challenge to clinicians.
Hsu, Donald I   +2 more
core   +1 more source

Ceftolozane/Tazobactam Dosing Requirements Against Bacteremia

open access: yesDose-Response, 2020
Objectives: To assess the probability of reaching adequate pharmacokinetic/pharmacodynamics values for ceftolozane/tazobactam at different doses and degrees of renal functions in patients with Pseudomonas aeruginosa bacteremia.
Jesus Ruiz   +6 more
doaj   +1 more source

Disproportionality Analysis of Fluoroquinolone‐Associated Peripheral Neuropathy in the FAERS Database (2007–2024)

open access: yesClinical and Translational Science, Volume 19, Issue 4, April 2026.
ABSTRACT Fluoroquinolones (FQs) are among the most frequently prescribed antibiotic classes worldwide. Despite their therapeutic versatility in treating bacterial infections, regulatory authorities recognized risks of persistent and potentially irreversible adverse effects, particularly peripheral neuropathy (PN).
Nimra Shamim   +5 more
wiley   +1 more source

Antimicrobial Resistance in Salmonella Across Aquaculture, Seafood and Related Aquatic Environments: A Scoping Review With Exploratory Textual Analysis

open access: yesReviews in Aquaculture, Volume 18, Issue 2, March 2026.
This scoping review with textual analysis maps antimicrobial resistance in Salmonella across aquaculture, seafood, and related aquatic environments. Across 93 studies, recurrent MDR patterns suggest sentinel serotypes (S. Typhimurium, S. Newport) and a minimal antimicrobial susceptibility testing (AST) panel to guide matrix‐stratified One Health ...
Cristiane Coimbra de Paula   +8 more
wiley   +1 more source

Broadly Defined Antibiotic Adjuvants for Pseudomonas aeruginosa

open access: yesCanadian Journal of Infectious Diseases and Medical Microbiology, Volume 2026, Issue 1, 2026.
Pseudomonas aeruginosa is a widely distributed opportunistic pathogen with multiple drug resistance, making it particularly challenging to treat in lower respiratory tract infections. Its resistance mechanisms are complex, including low outer‐membrane permeability, efflux pump overexpression, biofilm formation, and quorum sensing (QS) activation ...
Zhihan Chen   +3 more
wiley   +1 more source

Home - About - Disclaimer - Privacy